NuvOx Therapeutics Inc
First-in-Class Oxygen Therapeutic
Nuvoxpharma.com | Rong Wang| rwang@nuvoxpharma.com |520-624-6688

COMPANY OVERVIEW

A Phase IIb platform biotech company, NuvOx develops a drug that improves the flow of oxygen from lungs to blood and from blood to tissue. Our first-in-class oxygen therapeutic will treat life-threatening diseases where hypoxia plays a role (hypoxia weakens effectiveness for cancer treatments and causes brain death in stroke). Our product is the first material to reverse tissue hypoxia. Carrying ~1,000 x as much O_2 as liquids, it is injected IV and is fully synergistic with standard of care (SOC). We have positive Phase Ib/IIa human data in glioblastoma (GBM) and stroke, pre-clinical data in immuno-oncology and acute respiratory distress syndrome (ARDS). Our product is de-risked: Similar technology was commercialized as #1 selling contrast agent worldwide. We have safety data from > 2,000 subjects, strong patent protection, non-dilutive funding, and full-fledged organization and facility infrastructure.

MARKET & COMMERCIALIZATION STRATEGY

- GBM $300M+ worldwide revenue, entry point to 17bn+ oncology Serviceable Available Market (SAM)
- Stroke $4bn+ worldwide revenue
- ARDS: $1-2bn worldwide revenue

Our first customers are comprehensive centers for cancer, stroke, and respiratory care. We intend to leverage our trial sites and KOL for initial launch, after which we partner with large pharma companies or develop our own global commercial team.

TECHNICAL & COMPETITIVE ADVANTAGE

Our product utilizes a gas-based active pharmaceutical ingredient (API), emulsified into liquid with a unique surfactant. This unique formulation creates a much safer and more effective method to deliver oxygen (200-1000x safer and more effective than similar material, and 1000x more effective than liquid). Compared to other clinical stage companies to address oncology and stroke as radiosensitizer and neuroprotectant, we are more advanced in clinical development, have broader and deeper market coverage, and fit with SOC perfectly. For ARDS, using our product can avoid invasive ventilators and the injury/mortality associated with it.

REGULATORY STRATEGY & INTELLECTUAL PROPERTY

- 8 patent families, 7 issued US patents and foreign equivalent; New IP to file for new critical excipient
- Potentially regulated as biologics: 12 years market exclusivity; Orphan drug GBM & Sickle cell: Fast Track pathway
- 10 employees and experienced consultants; In-house manufacturing, ISO7/ISO5 clean room; Established QMS

KEY MILESTONES

- 2022: Clean room certified as ISO7/ISO5 and clinical production; 4 sites signed for GBM Phase IIb trial; $2M non-dilutive funding; $3M raised (out of $5M bridge round); Recommended for 1.5M £ grant from UK NIHR for Phase IIb stroke trial; Converted to Delaware C Corp
- Q1 2023: Commence enrollment for GBM Phase IIb trial; $3.6M non-dilutive funding applications in pipeline
- Q2/3 2023: Close $5M bridge; Commence Phase IIb stroke trial in UK
- H2 2023: Start raising Series B

CAPITALIZATION HISTORY

YEAR	FUNDING TYPE	DESCRIPTION	AMOUNT
To date	Non-dilutive	NIH, DoD, and NIHR Grants	$13M Equiv. (half active)
2019 & Prior	Series A	Individual investors (Raised)	$10.4M
2021-current	Bridge	Angels (Currently Open)	$5M
2023 and beyond	Series B	Institutions (To Commence 2023)	$25-50M

USE OF PROCEEDS

The current raise ($5M bridge), together with non-dilutive funding, will support successful completion of Phase IIb GBM trial and Phase IIb stroke trial. Most of the proceeds will be used for trial expenses.

MANAGEMENT TEAM

- **CEO/Co-Founder—Dr. Evan Unger:** 4 biotech/3 FDA approved drugs**;** Multiple successful exits (>20x ROI)
- **COO/CFO—Rong Wang, CFA:** 20+ years in public and VC life sciences space; Multiple successful exits
- **CSO/Co-Founder—Dr. Jenny Johnson:** Award winning scientist/regulatory/quality, Roche
- **SVP Strategy—Dr. Nina Ossana:** IP examiner and Tech Transfer – Johns Hopkins Medical School
- **Board:** Include former Roche Executive and 17th Surgeon General of the United States
- **SAB:** CMC/Supply Chain expert – CDO of public company, and world-renowned neuro-oncologist